Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 | Zendy

Kris V. Kowdley | Zendy; Eric Lawitz | Zendy; Fred Poordad | Zendy; Daniel E. Cohen | Zendy; David R. Nelson | Zendy; Stefan Zeuzem | Zendy; Gregory T. Everson | Zendy; Paul Y. Kwo | Zendy; Graham R. Foster | Zendy; Mark Sulkowski | Zendy; Wangang Xie | Zendy; Edward Tam | Zendy; George Liossis | Zendy; Lois Larsen | Zendy; Amit Khatri | Zendy; Thomas Podsadecki | Zendy; Barry Bernstein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

Author(s) -

Kris V. Kowdley,

Eric Lawitz,

Fred Poordad,

Daniel E. Cohen,

David R. Nelson,

Stefan Zeuzem,

Gregory T. Everson,

Paul Y. Kwo,

Graham R. Foster,

Mark Sulkowski,

Wangang Xie,

Edward Tam,

George Liossis,

Lois Larsen,

Amit Khatri,

Thomas Podsadecki,

Barry Bernstein

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1306227

Subject(s) - medicine , virology , genotype , hepatitis c virus , interferon , hepacivirus , virus , immunology , genetics , gene , biology

An interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r), the nonnucleoside polymerase inhibitor ABT-333, and ribavirin showed efficacy against the hepatitis C virus (HCV) in a pilot study involving patients with HCV genotype 1 infection. The addition of another potent agent, the NS5A inhibitor ABT-267, may improve efficacy, especially in difficult-to-treat patients. This study was designed to evaluate multiple regimens of direct-acting antiviral agents and ribavirin in patients with HCV genotype 1 infection who had not received therapy previously or who had no response to prior therapy with pegylated interferon and ribavirin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research